Fortress Biotech, Inc. (FBIOP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 30M 60M 90M FY13: 0 FY14: 0 FY15: 863K FY16: 16.5M FY17: 17.2M FY18: 26.9M FY19: 36.6M FY20: 45.6M FY21: 68.8M FY22: 75.7M FY23: 84.5M FY24: 57.7M FY25: 63.3M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 25M 50M 75M FY17: 13.6M FY18: 20.8M FY19: 26.1M FY20: 31M FY21: 36.7M FY22: 45M FY23: 61.6M FY24: 36.8M FY25: 42.3M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Income Annual

-210M -140M -70M 0 70M 140M 210M FY09: -2.6M FY10: -9.2M FY11: -35M FY12: -27.2M FY13: -35.8M FY14: -20.7M FY15: -50.5M FY16: -65.7M FY17: -89.8M FY18: -120M FY19: -110.8M FY20: -94.3M FY21: -188.5M FY22: -203.6M FY23: -142.3M FY24: -110.4M FY25: -70.2M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-90M -60M -30M 0 30M 60M 90M FY07: -2.6M FY08: -3.8M FY09: -3.7M FY10: -10M FY11: -36.4M FY12: -27.6M FY13: -37.2M FY14: -20.4M FY15: -48.4M FY16: -55.1M FY17: -66.9M FY18: -84.1M FY19: -40M FY20: -46.5M FY21: -64.7M FY22: -86.6M FY23: -60.6M FY24: -46M FY25: 6.8M FY07 FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 15M 30M 45M FY17: 3.7M FY18: 6.1M FY19: 10.5M FY20: 14.6M FY21: 32.1M FY22: 30.8M FY23: 22.9M FY24: 20.9M FY25: 20.9M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-210M -140M -70M 0 70M 140M 210M FY09: -2.4M FY10: -5.7M FY11: -11M FY12: -23.2M FY13: -29.6M FY14: -16.3M FY15: -20.4M FY16: -45.8M FY17: -81.3M FY18: -98.8M FY19: -95M FY20: -83.7M FY21: -116.5M FY22: -179.4M FY23: -128.2M FY24: -80.2M FY25: -65.8M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-210M -140M -70M 0 70M 140M 210M FY11: -11M FY12: -23.2M FY13: -29.7M FY14: -16.3M FY15: -20.7M FY16: -52.2M FY17: -82M FY18: -105.9M FY19: -97.3M FY20: -85.6M FY21: -121.1M FY22: -182.1M FY23: -128.3M FY24: -80.2M FY12 FY14 FY16 FY18 FY20 FY22 FY24

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 30M 60M 90M FY21: 81.7M FY22: 5.9M FY23: 8.1M FY24: 20.8M FY25: 27.9M FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q2 '11: -7.11 Q3 '11: -7.15 Q4 '11: -7.35 Q1 '12: -2.99 Q2 '12: -1.69 Q3 '12: -1.45 Q4 '12: -1.29 Q1 '13: -1.29 Q2 '13: -1.33 Q3 '13: -1.33 Q4 '13: -1.24 Q1 '14: -1.10 Q2 '14: -0.85 Q3 '14: -0.74 Q4 '14: -0.57 Q1 '15: -0.67 Q2 '15: -0.70 Q3 '15: -1.03 Q4 '15: -1.23 Q1 '16: -1.23 Q2 '16: -1.38 Q3 '16: -1.24 Q4 '16: -1.37 Q1 '17: -1.36 Q2 '17: -1.48 Q3 '17: -1.83 Q4 '17: -1.65 Q1 '18: -1.84 Q2 '18: -1.91 Q3 '18: -1.61 Q4 '18: -1.91 Q1 '19: -1.40 Q2 '19: -1.14 Q3 '19: -0.99 Q4 '19: -0.71 Q1 '20: -0.92 Q2 '20: -0.87 Q3 '20: -0.85 Q4 '20: -0.64 Q1 '21: -0.56 Q2 '21: -0.41 Q3 '21: -0.47 Q4 '21: -0.79 Q1 '22: -0.86 Q2 '22: -1.08 Q3 '22: -4.93 Q4 '22: -9.37 Q1 '23: -9.40 Q2 '23: -12.79 Q3 '23: -9.62 Q4 '23: -5.33 Q1 '24: -6.16 Q2 '24: -3.24 Q3 '24: -3.06 Q4 '24: -2.79 Q1 '25: -2.23 Q2 '25: -1.05 Q3 '25: -0.18 Q4 '25: -0.07 Q1 '26: 3.23 Q1 '12 Q1 '14 Q1 '16 Q1 '18 Q1 '20 Q1 '22 Q1 '24 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.